Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Toripalimab in Small Cell Esophageal Carcinoma
NCT03811379Phase 2Unknown
- Sponsor
- Sun Yat-sen University
- Start
- Nov 2018
- Primary completion
- Dec 2020
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of toripalimab in small cell carcinoma of the esophagus (SCEC), sponsored by Sun Yat-sen University. Primary endpoint: Objective Response Rates up to 2 years. Status: unknown.
02
Drugs
toripalimab
03
Conditions
small cell carcinoma of the esophagus (SCEC)
Beyond the preview
Go deeper on NCT03811379.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03811379.